⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELDN News
Eledon Pharmaceuticals, Inc. Common Stock
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
globenewswire.com
NCEL
ELDN
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
globenewswire.com
NCEL
ELDN
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
prnewswire.com
ELDN
SANA
VCEL
LCTX
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
globenewswire.com
ELDN
Form 8-K
sec.gov
ELDN
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
globenewswire.com
ELDN
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
globenewswire.com
ELDN
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
prnewswire.com
ELDN
NCEL
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
ELDN
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
ELDN